Author
Home > Health > What is the Difference Between Bisphosphonates and Denosumab?

Guilherme Mazui

•4 minutes to read

What is the Difference Between Bisphosphonates and Denosumab?

🆚 Go to Comparative Table 🆚

Bisphosphonates and denosumab are both used to treat postmenopausal osteoporosis, but they have different mechanisms of action and varying levels of effectiveness. Here are the main differences between the two:

  1. Mechanism of Action: Bisphosphonates work by binding to bone mineral, impairing the ability of bone-resorbing osteoclasts to attach, reducing osteoclast recruitment, and promoting osteoclast apoptosis. Denosumab, on the other hand, directly binds to the RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) and inhibits the survival and differentiation of osteoclasts.
  2. Antiresorptive Effect: Denosumab has a greater antiresorptive effect than bisphosphonates. It has been shown to increase bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck more significantly than bisphosphonates.
  3. Cost and Administration: Denosumab is typically more expensive than bisphosphonates. However, it is administered through two annual injections, which may increase compliance compared to some bisphosphonates that require more frequent dosing.
  4. Safety and Tolerability: Denosumab has been reported to be better tolerated than bisphosphonates. The safety profiles of denosumab and bisphosphonates were found to be similar in a meta-analysis of randomized controlled trials.
  5. Fracture Risk Reduction: Despite denosumab increasing BMD at both the hip and spine in all trials, it did not reduce fracture risk compared to bisphosphonates.

In conclusion, denosumab and bisphosphonates have different mechanisms for treating postmenopausal osteoporosis, with denosumab having a greater antiresorptive effect and potentially being better tolerated. However, denosumab is more expensive and has not been shown to reduce fracture risk more effectively than bisphosphonates. The choice between the two depends on individual patient factors, such as cost, administration preferences, and tolerability.

On this page
  • What is the Difference Between Bisphosphonates and Denosumab?
  • Comparative Table: Bisphosphonates vs Denosumab

    • Comparative Table: Bisphosphonates vs Denosumab

    Property Bisphosphonates Denosumab
    Mechanism of Action Selectively adhere to and remain within bone, inactivating or promoting apoptosis of osteoclasts Fully human monoclonal IgG2 antibody that binds to the receptor activator of nuclear factor kappa-B ligand (RANKL), inhibiting the development, activation, and survival of osteoclasts
    Antiresorptive Effect Persistent but not progressive, resulting in increased bone mineral density (BMD) over the first few years, followed by a plateau Progressive, resulting in increased BMD as long as treatment is continued
    Bone Mineral Density Increases BMD at the lumbar spine, total hip, and femoral neck, but to a lesser extent than denosumab Increases BMD at the lumbar spine, total hip, and femoral neck more significantly than bisphosphonates
    Treatment Frequency Generally administered as daily or weekly oral medications or as intravenous infusions Administered as subcutaneous injections every 6 months
    Side Effects Can cause gastrointestinal side effects and may be associated with renal toxicity May be better tolerated than bisphosphonates, with less renal impairment and acute-phase reactions
    Cost Generally less expensive than denosumab Slightly more costly than bisphosphonates
    Read more:

    Guilherme Mazui

    Guilherme Mazui is graduated in journalism from the Federal University of Minas Gerais (UFMG) and a master's degree in Communication from the University of São Paulo (USP). In addition, he has experience in advertising writing and has worked as a content editor in several companies.